HIFU for Prostate Cancer: A Precision Approach to Focal Therapy

For men diagnosed with localized prostate cancer, the treatment journey often feels like a choice between two extremes: the “wait and see” approach of active surveillance or the life-altering impact of radical interventions. However, a significant shift toward focal management is bridging this gap. High-intensity focused ultrasound (HIFU) has emerged as a promising middle path, offering a way to target malignant tissues while prioritizing the patient’s quality of life.

What is HIFU?

High-intensity focused ultrasound (HIFU) is a minimally invasive modality used to treat localized prostate cancer. Unlike whole-gland therapies, focal HIFU selectively targets cancerous regions. The process works by delivering concentrated ultrasonic waves toward a malignant lesion, generating heat above 65°C. This intense heat destroys the targeted area through a process called coagulative necrosis, effectively eradicating the cancer while sparing the surrounding healthy tissue.

The Importance of Precise Patient Selection

Not every patient is a candidate for focal HIFU. Successful outcomes depend on rigorous patient selection to ensure the cancer is localized and manageable without radical surgery. Clinicians primarily use two tools for this process:

• Multiparametric MRI (mpMRI): This imaging is essential for identifying well-defined index lesions.
• Genomic Testing: This serves as a critical safety check for risk stratification, helping doctors determine if a focal approach is safe for the specific genetic profile of the tumor.

Technological Advancements in Delivery

Modern robotic platforms have enhanced the precision of HIFU. These systems now allow for real-time ultrasound fusion and stepwise energy delivery. This intraoperative precision helps surgeons navigate variables such as prostatic edema (swelling) and ensures the preservation of healthy tissue. Some practitioners use intraoperative transrectal prostate compression to reduce prostatic swelling and prevent the target region from shifting during the procedure.

Comparing Outcomes: Focal vs. Radical Treatment

Oncological Efficacy

Evidence suggests that HIFU can provide strong oncologic control. A multi-center prospective study monitored patients for a median of 48 months and reported impressive 7-year biochemical disease-free survival (BDFS) rates based on risk levels:

• Low-risk disease: 89.6%
• Intermediate-risk disease: 88.5%
• High-risk disease: 81.6%

In cases of whole-gland HIFU, a systematic review found that the 10-year prostate cancer-specific survival rate ranged between 90% and 100% across three different studies. However, BDFS rates for whole-gland treatment varied more widely, ranging from 21.7% to 89.2%.

Functional Outcomes and Side Effects

The primary appeal of HIFU is the preservation of functional outcomes. When compared to robotic-assisted radical prostatectomy, HIFU demonstrates a more favorable adverse effect profile, particularly regarding the preservation of erectile function and urinary continence. It also offers reduced bowel toxicity when compared to ultra-hypofractionated radiation therapy.

While generally safer, HIFU is not without risks. A systematic review of whole-gland HIFU noted potential side effects, including:

• Erectile dysfunction: Reported in 11.6% to 77.1% of patients.
• Urinary incontinence: Reported in 0% to 22.7% of patients.
• Urinary tract infections: Reported in 1.5% to 47% of patients.

Post-Ablation Surveillance and Recovery

Monitoring a patient after HIFU requires expert radiologic assessment. Because the ablation process can induce scarring and distort anatomical planes, it can be demanding to distinguish between treatment-induced fibrosis and a nodular recurrence. To manage this, clinicians use:

• Multiparametric MRI
• PSMA-PET scans

If recurrence is detected, salvage therapies remain a viable and safe option for patients who have previously undergone HIFU.

Frequently Asked Questions

Is HIFU a replacement for surgery?

HIFU is not a universal replacement for surgery but rather a “middle path.” It is designed for selected patients with localized prostate cancer who wish to avoid the significant morbidities associated with radical prostatectomy, such as severe urinary incontinence and erectile dysfunction.

How does HIFU differ from radiation therapy?

While both target cancer, HIFU uses focused ultrasound waves to create heat and cause necrosis. According to CancerNetwork, HIFU offers reduced bowel toxicity compared to ultra-hypofractionated radiation therapy.

What is the success rate of HIFU?

Success depends on the risk category. For focal HIFU, 7-year biochemical disease-free survival rates have been reported as high as 89.6% for low-risk patients, and 81.6% for high-risk patients, as detailed in research published via Nature.